ThermoGenesis Holdings, Inc. (THMO) Income Statement Analysis

See more : Eurocharm Holdings Co., Ltd. (5288.TW) Income Statement Analysis – Financial Results

Complete financial analysis of ThermoGenesis Holdings, Inc. (THMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ThermoGenesis Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Cipher Mining Inc. (CIFRW) Income Statement Analysis – Financial Results
Takizawa Ham Co., Ltd. (2293.T) Income Statement Analysis – Financial Results
Garware Technical Fibres Limited (GARFIBRES.NS) Income Statement Analysis – Financial Results
Century Entertainment International Holdings Limited (0959.HK) Income Statement Analysis – Financial Results
Ameren Illinois Company (AILLI) Income Statement Analysis – Financial Results

ThermoGenesis Holdings, Inc. (THMO)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.thermogenesis.com

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986
Revenue	9.45M	10.48M	9.29M	9.74M	13.05M	9.67M	12.03M	14.53M	11.93M	16.04M	15.99M	17.96M	19.02M	23.40M	23.09M	19.80M	21.95M	16.75M	12.05M	10.18M	11.65M	10.19M	9.55M	5.79M	4.21M	5.10M	4.50M	6.60M	4.10M	3.30M	2.70M	2.00M	1.80M	1.80M	1.10M	1.20M	500.00K	100.00K
Cost of Revenue	7.51M	7.77M	5.80M	8.49M	7.35M	7.48M	7.72M	8.69M	9.19M	11.29M	10.10M	11.60M	12.69M	14.56M	15.64M	14.11M	14.98M	11.55M	7.71M	7.09M	7.84M	7.90M	7.56M	5.01M	4.25M	3.70M	5.00M	4.00M	1.60M	1.90M	1.40M	1.00M	1.20M	600.00K	400.00K	500.00K	100.00K	0.00
Gross Profit	1.93M	2.71M	3.49M	1.26M	5.70M	2.19M	4.31M	5.84M	2.74M	4.75M	5.89M	6.37M	6.33M	8.84M	7.45M	5.69M	6.97M	5.20M	4.34M	3.09M	3.80M	2.29M	1.99M	780.00K	-35.00K	1.40M	-500.00K	2.60M	2.50M	1.40M	1.30M	1.00M	600.00K	1.20M	700.00K	700.00K	400.00K	100.00K
Gross Profit Ratio	20.44%	25.85%	37.58%	12.92%	43.66%	22.67%	35.84%	40.20%	23.00%	29.60%	36.82%	35.43%	33.29%	37.76%	32.25%	28.75%	31.76%	31.03%	36.05%	30.34%	32.65%	22.45%	20.85%	13.47%	-0.83%	27.45%	-11.11%	39.39%	60.98%	42.42%	48.15%	50.00%	33.33%	66.67%	63.64%	58.33%	80.00%	100.00%
Research & Development	1.28M	1.66M	2.21M	2.48M	2.40M	3.01M	4.49M	2.50M	3.23M	5.94M	3.47M	2.99M	3.73M	3.00M	5.01M	5.22M	7.17M	4.11M	4.16M	5.67M	3.47M	2.94M	2.28M	1.78M	1.62M	2.00M	3.90M	3.60M	1.30M	400.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	5.73M	6.38M	8.29M	7.92M	10.87M	8.23M	10.70M	8.49M	5.65M	5.22M	5.47M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	1.95M	1.66M	1.36M	1.69M	1.53M	2.15M	2.97M	2.97M	2.96M	2.76M	3.20M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	7.22M	7.24M	8.52M	7.68M	8.03M	9.65M	9.01M	12.40M	10.38M	13.67M	11.46M	8.60M	7.98M	8.67M	7.69M	9.25M	10.17M	9.63M	7.16M	5.84M	5.17M	5.01M	4.84M	3.89M	4.20M	4.80M	4.60M	3.50M	1.60M	1.10M	1.80M	1.30M	1.90M	1.30M	1.10M	1.00M	1.30M	600.00K
Other Expenses	0.00	-3.00K	802.00K	-8.00K	-33.00K	-24.00K	0.00	180.00K	-44.00K	21.00K	6.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	10.54M	8.90M	10.72M	10.15M	10.43M	12.66M	13.51M	14.90M	13.61M	19.61M	14.93M	11.59M	11.71M	11.67M	12.70M	14.47M	17.34M	13.74M	11.31M	11.51M	8.65M	7.95M	7.13M	5.67M	5.82M	7.40M	9.00M	7.40M	3.10M	1.70M	1.90M	1.50M	2.10M	1.60M	1.30M	1.10M	1.40M	700.00K
Cost & Expenses	18.33M	16.68M	16.53M	18.64M	17.78M	20.14M	21.22M	23.58M	22.79M	30.90M	25.03M	23.19M	24.40M	26.24M	28.34M	28.58M	32.31M	25.29M	19.02M	18.60M	16.49M	15.85M	14.68M	10.68M	10.07M	11.10M	14.00M	11.40M	4.70M	3.60M	3.30M	2.50M	3.30M	2.20M	1.70M	1.60M	1.50M	700.00K
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.19M	1.77M	828.00K	216.00K	90.00K	0.00	110.00K	130.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	10.03M	5.62M	6.10M	7.91M	4.48M	2.70M	0.00	20.52M	7.99M	14.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.00K	23.00K	0.00	13.00K	1.11M	0.00	0.00	0.00	100.00K	0.00	0.00	0.00	0.00	0.00	200.00K	100.00K	0.00	0.00	0.00
Depreciation & Amortization	1.15M	926.00K	633.00K	754.00K	806.00K	670.00K	644.00K	830.00K	1.17M	1.35M	993.00K	538.00K	604.00K	466.00K	492.00K	474.00K	543.00K	549.00K	118.00K	367.00K	302.00K	266.00K	434.00K	485.00K	677.00K	600.00K	500.00K	300.00K	200.00K	200.00K	100.00K	200.00K	200.00K	300.00K	200.00K	100.00K	100.00K	100.00K
EBITDA	-7.74M	-5.27M	-6.60M	-8.16M	-4.73M	-42.30M	-8.55M	-8.42M	-9.70M	-13.49M	-8.05M	-4.69M	-4.78M	-2.37M	-4.76M	-8.30M	-9.82M	-7.99M	-6.85M	-8.06M	-4.54M	-5.40M	-4.70M	-4.41M	-5.18M	-5.40M	-9.00M	-4.50M	-400.00K	-100.00K	-500.00K	-300.00K	-1.30M	-100.00K	-400.00K	-300.00K	-900.00K	-500.00K
EBITDA Ratio	-81.95%	-50.27%	-62.36%	-83.75%	-30.47%	-101.51%	-71.11%	-55.41%	-81.66%	-84.07%	-50.33%	-38.13%	-25.10%	-10.12%	-20.63%	-41.94%	-44.76%	-47.71%	-56.87%	-79.15%	-39.00%	-52.99%	-49.23%	-76.07%	-122.94%	-105.88%	-200.00%	-68.18%	-9.76%	-12.12%	-18.52%	-15.00%	-72.22%	-5.56%	-36.36%	-33.33%	-200.00%	-600.00%
Operating Income	-8.61M	-6.19M	-7.23M	-8.90M	-4.73M	-43.55M	-9.20M	-9.37M	-10.87M	-14.86M	-9.04M	-3.07M	-5.38M	-2.84M	-5.25M	-8.78M	-10.37M	-8.54M	-6.97M	-8.42M	-4.84M	-5.66M	-5.14M	-4.89M	-5.85M	-6.00M	-9.50M	-4.80M	-600.00K	-300.00K	-600.00K	-500.00K	-1.50M	-400.00K	-600.00K	-400.00K	-1.00M	-600.00K
Operating Income Ratio	-91.16%	-59.08%	-77.80%	-91.29%	-36.28%	-450.22%	-76.47%	-64.50%	-91.08%	-92.63%	-56.55%	-17.06%	-28.28%	-12.12%	-22.76%	-44.34%	-47.24%	-50.99%	-57.85%	-82.76%	-41.59%	-55.60%	-53.78%	-84.44%	-139.02%	-117.65%	-211.11%	-72.73%	-14.63%	-9.09%	-22.22%	-25.00%	-83.33%	-22.22%	-54.55%	-33.33%	-200.00%	-600.00%
Total Other Income/Expenses	-10.31M	-5.62M	-4.65M	-7.92M	-5.37M	-2.13M	-1.00M	-20.53M	-7.72M	7.00K	6.00K	-21.00K	393.00K	268.00K	61.00K	228.00K	1.19M	1.77M	0.00	202.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	300.00K	600.00K	0.00	0.00	0.00	0.00	100.00K	100.00K	100.00K
Income Before Tax	-18.92M	-11.81M	-11.88M	-16.81M	-10.10M	-45.67M	-10.02M	-29.77M	-18.59M	-14.85M	-9.03M	-3.09M	-4.99M	-2.57M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-300.00K	-900.00K	-500.00K
Income Before Tax Ratio	-200.31%	-112.68%	-127.82%	-172.53%	-77.40%	-472.19%	-83.29%	-204.94%	-155.82%	-92.58%	-56.51%	-17.18%	-26.21%	-10.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-25.00%	-180.00%	-500.00%
Income Tax Expense	0.00	5.07M	6.40M	7.44M	3.83M	-4.73M	-4.48M	-673.00K	7.95M	35.00K	-403.00K	-2.14M	0.00	0.00	-61.00K	-228.00K	-1.19M	-1.77M	-828.00K	-202.00K	-67.00K	-61.00K	-97.00K	1.84M	-36.00K	100.00K	100.00K	0.00	0.00	-200.00K	0.00	-200.00K	0.00	300.00K	200.00K	100.00K	100.00K	200.00K
Net Income	-17.98M	-11.27M	-11.38M	-16.35M	-9.50M	-39.72M	-4.57M	-29.10M	-18.59M	-14.85M	-8.63M	-3.09M	-4.99M	-2.57M	-5.19M	-8.55M	-9.18M	-6.78M	-6.14M	-8.22M	-4.78M	-5.60M	-5.04M	-6.73M	-5.82M	-6.10M	-9.60M	-4.80M	-600.00K	-100.00K	0.00	-300.00K	-1.50M	-700.00K	-800.00K	-500.00K	-1.10M	-800.00K
Net Income Ratio	-190.31%	-107.51%	-122.43%	-167.81%	-72.79%	-410.63%	-37.97%	-200.31%	-155.82%	-92.58%	-53.99%	-17.18%	-26.21%	-10.97%	-22.49%	-43.18%	-41.83%	-40.45%	-50.98%	-80.77%	-41.02%	-55.00%	-52.76%	-116.25%	-138.16%	-119.61%	-213.33%	-72.73%	-14.63%	-3.03%	0.00%	-15.00%	-83.33%	-38.89%	-72.73%	-41.67%	-220.00%	-800.00%
EPS	-7.59	-20.45	-43.41	-117.20	-151.09	-971.34	-203.28	-1.32K	-2.78K	-3.31K	-3.21K	-1.68K	-2.74K	-1.56K	-3.33K	-5.49K	-5.93K	-4.42K	-4.46K	-6.52K	-4.12K	-5.51K	-5.15K	-7.63K	-8.44K	-10.66K	-18.29K	-10.91K	-1.70K	-283.29	0.00	-1.17K	-6.07K	-3.20K	-4.65K	-3.73K	-8.27K	-6.67K
EPS Diluted	-7.59	-20.45	-43.41	-117.20	-151.09	-971.34	-203.28	-1.32K	-2.78K	-3.31K	-3.21K	-1.68K	-2.74K	-1.56K	-3.33K	-5.49K	-5.93K	-4.42K	-4.46K	-6.52K	-4.12K	-5.51K	-5.15K	-7.63K	-8.44K	-10.66K	-18.29K	-10.91K	-1.70K	-283.29	0.00	-1.17K	-6.07K	-3.20K	-4.65K	-3.73K	-8.27K	-6.67K
Weighted Avg Shares Out	2.37M	550.99K	262.13K	139.51K	62.86K	40.89K	22.46K	22.04K	6.69K	4.48K	2.69K	1.84K	1.82K	1.65K	1.56K	1.56K	1.55K	1.53K	1.38K	1.26K	1.16K	1.02K	978.00	883.00	689.00	572.00	525.00	440.00	353.00	353.00	282.00	257.00	247.00	219.00	172.00	134.00	133.00	120.00
Weighted Avg Shares Out (Dil)	2.37M	550.99K	262.13K	139.51K	62.86K	40.89K	22.46K	22.04K	6.69K	4.48K	2.69K	1.84K	1.82K	1.65K	1.56K	1.56K	1.55K	1.53K	1.38K	1.26K	1.16K	1.02K	978.00	883.00	689.00	572.00	525.00	440.00	353.00	353.00	282.00	257.00	247.00	219.00	172.00	134.00	133.00	120.00

ThermoGenesis Holdings Announces 2020 Year End Financial Results and Provides Corporate Update

March 17, 2021prnewswire.com

RANCHO CORDOVA, Calif., March 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended...

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2020 and Provide a Corporate Strategic Update

March 10, 2021prnewswire.com

RANCHO CORDOVA, Calif., March 10, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth...